samedan logo
 
 
spacer
home > ict > autumn 2017 > end point: a costly cause
PUBLICATIONS
International Clinical Trials

End Point: A Costly Cause

Our sister publication, Pharmafile (in its spring 2017 edition), listed the predicted top 50 selling products in the world in 2022. I was astonished to note that the vast majority of these products are biotechnology-based products rather than traditional molecules. Fewer than 10 small molecules feature on this list. In a separate article, Pharmafile discusses the world of $100,000 products and how this will impact on the future of healthcare. If you examine the list of these drugs a little further, you will note that the majority of them are not for rare conditions, but unusual ones. I remember that while working for the agrochemical industry, a development scientist at one of the leading US companies told me that, if the new pesticide did not work on corn or cotton, it would never make economic sense to develop it. In the same group, a farmer who grew courgettes said ‘What hope have I got for the future then?’ The pharmaceutical industry is not yet in this parlous condition, but it may be that the era of the blockbuster is ending and precision medicine will take its place.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

Cambridge, UK, 22 January 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.
More info >>

White Papers

galenIQ - The smart excipient

BENEO-Palatinit GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

Clinical Trial Supply New England 2018

7-8 March 2018, Boston, MA, USA

Clinical Trial Supply New England has now reached its 7th birthday! For the 7th annual Clinical Trial Supply New England 2018 conference, we have speakers who will focus primarily on discussing case studies, drawing from their own experiences to share the highs and lows for you to adopt in your trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement